Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CBT-502 |
Synonyms | |
Therapy Description |
CBT-502 is a humanized monoclonal antibody that targets PD-L1 (CD274), potentially leading to antitumor activity (PMID: 35675031). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CBT-502 | CBT502|CBT 502|TQB2450|TQB 2450|TQB-2450|Benmelstobart | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | CBT-502 is a humanized monoclonal antibody that targets PD-L1 (CD274), potentially leading to antitumor activity (PMID: 35675031). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|